Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does FULVESTRANT Cause Malignant neoplasm progression? 3,221 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 3,221 reports of Malignant neoplasm progression have been filed in association with FULVESTRANT (FULVESTRANT). This represents 18.2% of all adverse event reports for FULVESTRANT.

3,221
Reports of Malignant neoplasm progression with FULVESTRANT
18.2%
of all FULVESTRANT reports
486
Deaths
402
Hospitalizations

How Dangerous Is Malignant neoplasm progression From FULVESTRANT?

Of the 3,221 reports, 486 (15.1%) resulted in death, 402 (12.5%) required hospitalization, and 81 (2.5%) were considered life-threatening.

Is Malignant neoplasm progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for FULVESTRANT. However, 3,221 reports have been filed with the FAERS database.

What Other Side Effects Does FULVESTRANT Cause?

Fatigue (1,840) Death (1,677) Metastases to bone (1,525) Nausea (1,510) Neutropenia (1,486) Metastases to liver (1,241) Breast cancer metastatic (1,165) Diarrhoea (1,163) Dyspnoea (858) Neoplasm progression (853)

What Other Drugs Cause Malignant neoplasm progression?

PEMBROLIZUMAB (10,111) NIVOLUMAB (9,363) ENZALUTAMIDE (4,696) CARBOPLATIN (4,177) EVEROLIMUS (3,789) PACLITAXEL (3,484) LETROZOLE (3,445) IPILIMUMAB (3,296) LENVATINIB (2,929) OSIMERTINIB (2,920)

Which FULVESTRANT Alternatives Have Lower Malignant neoplasm progression Risk?

FULVESTRANT vs FURAZOLIDONE FULVESTRANT vs FUROSEMIDE FULVESTRANT vs FUROSEMIDE\SPIRONOLACTONE FULVESTRANT vs FUSIDATE FULVESTRANT vs FUSIDIC ACID

Related Pages

FULVESTRANT Full Profile All Malignant neoplasm progression Reports All Drugs Causing Malignant neoplasm progression FULVESTRANT Demographics